This study aimed to evaluate the real-world effectiveness and safety of T-DXd in a large number of patients with HER2-positive, unresectable, advanced or recurrent gastric cancer (gastric adenocarcinoma or GEJ adenocarcinoma). The gene discussed is ERBB2; the disease is gastric cancer.